RxDoctor Payments Data

Bayo Owens

Psychiatric/Mental Health · Middletown, RINPI 1134884356

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.5% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,915 and has fallen 60.3% since, to $1,157 in 2025. Among psychiatric/mental health clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,423in general payments, 2019–2025

Across 191 payments — averaging $28.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$716
  • Teva Pharmaceuticals USA, Inc.$670
  • Neurocrine Biosciences, Inc.$587
  • Otsuka America Pharmaceutical, Inc.$421
  • Alkermes, Inc.$408
  • plus $2K from 11 others

What the payments were for

  • Food & beverage$5,17895%
  • Education$2455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,423 in reported general payments places this provider in the 90th percentile of 196 psychiatric/mental health providers in Rhode Island.

See all psychiatric/mental health providers in Rhode Island

Most prescribed under Part D

DrugClaimsCost to plans & patients
HetliozTasimelteon11$234,623
IngrezzaValbenazine Tosylate14$115,512
AuvelityDextromethorphan Hbr/Bupropion12$7,973
Aripiprazole32$2,143
Venlafaxine Hcl ErVenlafaxine Hcl24$1,528
Buspirone Hcl97$1,336
Olanzapine28$1,166
Hydroxyzine Hcl95$1,068
Atomoxetine Hcl17$767
Mirtazapine38$714
Quetiapine Fumarate71$624
Sertraline Hcl28$351
Donepezil Hcl16$253
Benztropine Mesylate32$211
Divalproex Sodium13$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Hetlioz$107$234,62311 claims
Neurocrine Biosciences, Inc.Ingrezza$587$115,51214 claims
Axsome Therapeutics, Inc.Auvelity$86$7,97312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 196 psychiatric/mental health providers in Rhode Island.

Other psychiatric/mental health in Middletown

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →